Skip to content

Psilocybin research published in 2023

Page 2 of 19: studies 21 to 40 of 375, newest first. Back to the psilocybin overview

Studies

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes

JAMA Psychiatry December 6, 2023 Tammy Miller, Jeffrey LaPratt, Kimberly Swartz et al. 101 citations

Importance Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. Objective To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode. Design, Setting, and...

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Frontiers in Psychiatry December 6, 2023 Elliot Marseille, Manish Agrawal, Paul Thambi et al. 40 citations

Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician...

An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture

Molecules December 5, 2023 Marjolein Doesburg-Van Kleffens, Amy Marisa Zimmermann-Klemd, Carsten Gründemann 13 citations

Peyote (Lophophora williamsii) is a cactus that contains various biologically active alkaloids—such as pellotine, anhalonidine, hordenine and mescaline. Here, mescaline induces the psychoactive effects of peyote through the activation of the serotonin 5-HT2A receptor and the subsequent release of calcium (Ca2+) from the endoplasmic reticulum (ER). Moreover, an evaluation of the therapeutic...

Peer support and psychedelics.

Journal of Military, Veteran and Family Health December 1, 2023 Zachary Skiles, James R Dixon, Dan Friedrich et al.

The field of psychedelic-assisted psychotherapy and state-run psychedelic services will need to adequately train and certify facilitators to meet the anticipated demand for access. This article explores the role of peer support in the setting of medical and non-medical supervised psychedelic administration. Existing peer-support frameworks from both the psychedelic and the Veteran communities...

Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations

Current Biology December 1, 2023 Alistair R. Mctaggart, Stephen Mclaughlin, Jason C. Slot et al. 6 citations

Fungi that are edible or fermentative were domesticated through selective cultivation of their desired traits. Domestication is often associated with inbreeding or selfing, which may fix traits other than those under selection, and causes an overall decrease in heterozygosity. A hallucinogenic mushroom, Psilocybe cubensis, was domesticated from its niche in livestock dung for production of...

DOI: 10.1016/j.cub.2023.10.059 (opens in new tab) Psilocybin Domestication Selfing Genetic diversity +6

A history and future of psychedelics: The case of the Canadian military

Journal of Military, Veteran and Family Health December 1, 2023 Erika Dyck, Gregory P. Marchildon

LAY SUMMARY The historical relationship between psychedelic drugs and the military has often been characterized in terms of drug misuse or the connection between drugs like d-lysergic acid diethylamide (LSD) or psilocybin (magic mushrooms) contributing to anti-war sentiments. Recent clinical evidence, however, suggests these cultural associations may be overshadowing the potential for...

Studying classic psychedelics for the management of headache disorders: Considerations for Veterans

Journal of Military, Veteran and Family Health December 1, 2023 Emmanuelle A. D. Schindler, Jason J. Sico

LAY SUMMARY Patients with headache disorders, such as migraine or cluster headache, often have poor quality of life and can be disabled by their condition. Military members and Veterans have a high risk of developing a headache disorder, particularly because they are also at risk for brain injury through head trauma. New headache treatments are needed, because the available treatments may not...

Flies on ’Shrooms: Studying the Psychotherapeutic Potential of Psilocybin using Drosophila

American Entomologist December 1, 2023 Nicoletta Faraone 1 citation

Journal Article Flies on 'Shrooms: Studying the Psychotherapeutic Potential of Psilocybin using Drosophila Get access Nicoletta Faraone Nicoletta Faraone Search for other works by this author on: Oxford Academic Google Scholar American Entomologist, Volume 69, Issue 4, Winter 2023, Pages 32–35, https://doi.org/10.1093/ae/tmad063 Published: 19 December 2023

DOI: 10.1093/ae/tmad063 (opens in new tab) Psilocybin Drosophila subgenus Psychoanalysis Psychotherapist +2

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations

There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...

LSD-induced changes in the functional connectivity of distinct thalamic nuclei.

Neuroimage December 1, 2023 Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al. 27 citations

The role of the thalamus in mediating the effects of lysergic acid diethylamide (LSD) was recently proposed in a model of communication and corroborated by imaging studies. However, a detailed analysis of LSD effects on nuclei-resolved thalamocortical connectivity is still missing. Here, in a group of healthy volunteers, we evaluated whether LSD intake alters the thalamocortical coupling in a...

Preclinical models of treatment-resistant depression: challenges and perspectives.

Pharmacological Reports December 1, 2023 Magdalena Kolasa, Agata Faron-Górecka 18 citations

Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least...

The possible place for psychedelics in pharmacotherapy of mental disorders.

Pharmacological Reports December 1, 2023 Adam Wojtas 10 citations

Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the...

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings

Psychedelic Medicine December 1, 2023 Julia Malicki, Amelia Baltes, Christopher R. Nicholas et al. 7 citations

Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall...

Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain

Current Biology December 1, 2023 Nicholas Kolbman, Tiecheng Liu, Peter R. Guzzo et al. 21 citations

There is a renewed interest in psychedelic drugs as potential therapeutic agents for the treatment of psychiatric disorders. In particular, psilocybin has shown promise for the treatment of refractory depression1 and major depressive disorder2, and has also been explored as a treatment for tobacco and alcohol abuse3,4. However, despite suggestive evidence5,6, there has been no systematic study...

DOI: 10.1016/j.cub.2023.10.016 (opens in new tab) Psychedelics Psilocybin therapy Pain management Medical research +1

Psilocybin's Erasure of EGO

The Psychoanalytic Review December 1, 2023 Gary Ahlskog 2 citations

The psychoanalytic journey and the psilocybin journey both reveal unconscious dynamics. In this article a psychoanalyst discusses his own psilocybin journey. Similarities and differences between these journeys are discussed. Possibilities are offered for a dialogue in which psilocybin may contribute to psychoanalytic understanding and psychoanalysis may contribute to the understanding of...

DOI: 10.1521/prev.2023.110.4.457 (opens in new tab) Psilocybin Psychoanalytic theory Unconscious mind Psychoanalysis +3

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants

Chemical Reviews November 30, 2023 Wenwen Duan, Dongmei Cao, Sheng Wang et al. 62 citations

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated the traditional psychedelic substances like psilocybin as a class of rapid-acting and long-lasting antidepressants. However, there is a pressing need for rationally designed 5-HT2AR agonists that possess optimal...

Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials

Clinical Psychopharmacology and Neuroscience November 30, 2023 Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim et al. 16 citations

Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A...

The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review

Journal of Psychedelic Studies November 29, 2023 Lennart Wiepking, Eduard J. de Bruin, Alexandra Ghiţă 10 citations

Abstract Background and aims This scoping review employed a multifaceted conceptualization of well-being to examine how psilocybin use affects well-being and related sub-concepts in healthy individuals. It investigated which factors influence the relationship between psilocybin use and well-being, what research protocols have been employed, and what underlying mechanisms have been proposed in...

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review

Journal of Neurochemistry November 29, 2023 James J Gattuso, Carey Wilson, Anthony J. Hannan et al. 18 citations

Abstract Psilocybin is the main psychoactive compound found in hallucinogenic/magic mushrooms and can bind to both serotonergic and tropomyosin receptor kinase b (TrkB) receptors. Psilocybin has begun to show efficacy for a range of neuropsychiatric conditions, including treatment‐resistant depression and anxiety disorders; however, neurobiological mechanisms are still being elucidated....

DOI: 10.1111/jnc.16017 (opens in new tab) Animal models Psychiatric disorders Psilocybin research Psychiatric treatment +3